Donor immune cell therapy for blood cancers after transplant relapse
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a special type of donor immune cell infusion (called DLI) that has been processed to remove certain cells that might limit its effectiveness. It is for people whose blood cancer has come back after a stem cell transplant and who have not responded well to standard donor cell treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with leukemia, myelodysplasia, myeloproliferative disorder, or a lymphoproliferative disorder (such as CLL, myeloma, or lymphoma).
- You have had a stem cell transplant from a matched sibling, haplo-identical, or unrelated donor.
- Your cancer has returned (molecular, cytogenetic, or cytologic relapse) after your transplant.
- You have tried at least one standard donor lymphocyte infusion (DLI) and it did not work or only partially worked.
- You have frozen blood cells (lymphapheresis) that were collected and stored from your donor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving extra donor immune cells (called DLI) after a stem cell transplant can help prevent relapse in people with hard-to-treat myeloid cancers. It may be an option if you had active disease at transplant but then achieved a deep remission.
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
This early-phase study tests whether giving donor immune cells (DLI) that have been “depleted” of a specific marker (CD45RA) can lower the chance of the leukemia/lymphoma coming back after a half-matched stem cell transplant. It’s meant to be preventive, not treatment for an active relapse.
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
This trial looks at using low doses of cyclophosphamide or CNI (a type of immune-suppressing drug) to prevent graft-versus-host disease (GVHD) in people who get a donor lymphocyte infusion after their blood cancer returns. It may help control GVHD while still fighting the cancer.
This trial tests whether specially prepared donor immune cells can fight stubborn viral infections that did not get better with standard treatment. It is for people who have had a stem cell transplant and are still struggling with viruses like CMV, EBV, or others.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.